Blue Trust Inc’s Telesis Bio, Inc. Common Stock TBIO Stock Holding History

Blue Trust Inc’s Portfolio TBIO Stock Details TBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-2	Closed	–	–	2378
2022 Q2	$0	Buy	+2	New	+$138	﹤0.01%	2039

Other funds holding TBIO

Northpond Ventures Bethesda, Maryland $43.7M AUM 27.27% 1-Year Est. Return

PCM

Penn Capital Management Philadelphia, Pennsylvania $1.29B AUM 53.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Penbrook Management New York $157M AUM 46.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Blue Trust Inc's TBIO Position: Q3 2022 in Review

Blue Trust Inc sold out of Telesis Bio, Inc. Common Stock (TBIO) in Q3 2022, closing a stake of 2 shares.

Blue Trust Inc first reported a position in TBIO in Q2 2022 and held it in 1 quarter. The position peaked at $0 in Q2 2022. 32 funds tracked by Wall St. Rank hold TBIO as of Q3 2022.

Blue Trust Inc reported no remaining Telesis Bio, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Blue Trust Inc sold 2 Telesis Bio, Inc. Common Stock shares in Q3 2022.
Blue Trust Inc first reported a position in Telesis Bio, Inc. Common Stock in Q2 2022 and held it in 1 quarter.
Blue Trust Inc's Telesis Bio, Inc. Common Stock position peaked at $0 in Q2 2022.
32 funds tracked by Wall St. Rank held Telesis Bio, Inc. Common Stock as of Q3 2022.

Based on Blue Trust Inc's 13F filing for Q3 2022, filed 21 Oct 2022.